The CHMP recommended granting Repatha marketing authorization for: The treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Amgen recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings ...

The National Institute for Health and Care Excellence has taken a u-turn on its decision to bar NHS patients from access to Amgen’s cholesterol buster Repatha, the world’s first approved PCSK9 ...

Amgen has secured a recommendation for its new cholesterol drug Repatha (evolocumab) from NICE, giving it a major advantage on Sanofi/Regeneron's rival Praluent (alirocumab). NICE rejected any use of ...

THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ -- Amgen (AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a ...